Allergan Inc.’s (NYSE:AGN) reported on Wednesday that its second-quarter earnings climbed up 20% although an appreciated dollar hurt revenue pace at the manufacturer of Botox and medical devices.
For 2012, the firm lowered its outlook and now predicts per-share earnings of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion, in contrast with its earlier forecast of $4.13 to $4.19 and $5.65 billion to $5.85 billion.
Allergan announced a profit of $295.4 million, or 96 cents per share, which was higher from $246.6 million, or 79 cents per share, last year same quarter. Omitting takeover-associated charges and other items, earnings were higher at $1.07 from 96 cents. Sales moved up 5.2% to $1.49 billion.
One of the most critical factors in measuring the performance of a company is its Return on Assets ratio, which is an indicator of how profitable a company is relative to its total assets. Allergan, Inc. (NYSE:AGN) recently had ROA ratio of 11.84% while its market capitalization of 25.99 billion.
Previous month, AGN Inc stock price volatility was 2.45%. In its share capital AGN has 307.53 million outstanding shares among them 306.94 million shares have been floated in market exchange. AGN stock institutional ownership remained 91.75% while insider ownership included 0.14%.
The stock is of ahead its 52week low with +23.67% and lagging behind from its 52 week high price with -11.77%. Company’s beta coefficient included 0.82. Beta factor evaluates the amount of market risk associated with market trade.
AGN stock traded with a starting price of $84.85 and throughout the trading session climbed at a high of $91.94 and later when day-trade ended the stock finally surged +4.33% to $85.62 with a relative volume of 9.05 million shares.
Its competitor Johnson & Johnson (NYSE:JNJ) shares opened the session at $69.48 edged up +0.23% and finally settled at $69.38 with a relative trading volume of 11.68 million shares and Novartis AG (ADR) (NYSE:NVS) shares opened the session at $58.98 dropped -0.58% to settle at $58.28 with a relative trading volume of 10.08 million shares.